Drug Resistant Cancer Models from Biopsy Samples

LIDE’s Translational Medicine platform enables us to establish many acquired drug-resistant PDX models. Most of these models are generated from biopsy samples, not surgery samples like most other CROs.  Most surgery samples are treatment naïve at clinic, making biopsy samples the preferred choice for establishing mouse models or cell lines. LIDE's PDX models, established from biopsy samples that have already developed acquired drug resistant in the patient, is a more relevant choice for drug screening. The partial list is below but please contact us for the most up to date models.

With CR(Conditional Reprogramming) technology, we areable to establish PDX matching cell lines for drug screening, Pro-RNAi, CRISPR, luciferase labelling etc.  100+ PDX matching cell lines are available.  Please reference that list here.

Cancer Type Drug Resistance Genetic Alteration
NSCLC Erlotnib
Osimertinib
Crizotnib
Brigatnib
anti PD-1 ab
EGFR: exon19del/T790M/L858R/C797S/exon20ins
ALK: EML4-ALK/L11196M
cMET: ampli./exon14ski/CD47-MET
RET: KIF5B-RET
ROS1: CD74-ROS1/G2032R
KRAS: G12C
P13K: E726K
Breast Cancer CDK4/6i TNB/ER+
Multiple Myeloma Bortezomib CD47+/CD38+
Cholangiocarcinoma Paclitaxel KRAS: G12C
FGFR: BICC1-FGFR2
Colorectal Cancer Avastin KRAS: G12C
BFAR: V600E
Hematological Malignancy Rituximab
Imatinib
/
Gastric Cancer Herceptin HER2: ampli
KRAS: G12/G13D
Brain Cancer / EGFR: VIII
cMET: PTPPRZ1-MET
Melanoma anti PD-1 ab BRAF: V600E
Ovarian Cancer Platinum
PARpi
/

Table: LIDE PDX models with drug resistance

Download our model and cell line list here